Monitor Corporation's AI Lung Cancer Diagnosis Technology Designated as 'Provisional New Medical Technology'

Monitor Corporation's 'LuCAS plus' Changes the Landscape of the AI Lung Cancer Diagnosis Market – A Triumph in Being Selected as a 'New Medical Technology Subject to Evaluation Deferral' Monitor Corporation, a medical AI specialized company, has opened new horizons in the domestic medical AI market with its innovative AI lung cancer diagnosis solution, 'LuCAS plus,' which has been selected as a 'New Medical Technology Subject to Evaluation Deferral' by the National Evidence-based Healthcare Collaborating Agency (NECA). Building on this triumph, Monitor Corporation plans to accelerate business expansion in the domestic market and rapidly increase its market share. The 'New Medical Technology Subject to Evaluation Deferral' system is an advanced system that defers technology evaluation for a certain period to promote the on-site adoption of innovative medical technologies. Technologies selected under this system can be prescribed as non-reimbursable items in domestic medical institutions for up to 5 years, thereby lowering the barrier to initial market entry and providing an opportunity to secure rich clinical data. 'LuCAS plus' is particularly noteworthy as the first among AI solutions for lung cancer diagnosis that analyze chest CT images to be named under this system, officially recognizing its technological capability and potential. As a result, non-reimbursable prescriptions will be possible in medical institutions for up to 5 years starting from the second quarter of this year, and it is expected that the number of medical institutions wishing to adopt 'LuCAS plus' will explode. Monitor Corporation's 'LuCAS plus' is a solution that utilizes artificial intelligence technology to automatically analyze chest CT images and accurately diagnose suspicious lung cancer lesions, thereby assisting medical staff with diagnoses and dramatically increasing the efficiency of image interpretation. As the first Class 3 medical device in Korea to detect lung cancer, it has already been designated as an innovative medical device by the Ministry of Food and Drug Safety (MFDS), and is currently being actively utilized in over 100 medical institutions nationwide, proving its efficacy. Its expansion into the global market beyond the domestic market is also progressing smoothly. Recently, through collaboration with Dr. Net, a Japanese digital healthcare company, it has officially embarked on entering the Japanese medical market, and starting from April, when Japan's fiscal year begins, it is highly anticipated that its adoption by medical institutions within Japan will further expand. Lee Kyung-jun, CEO of Monitor Corporation, emphasized through this selection, "'LuCAS plus' will be able to settle into the domestic medical field more quickly and accumulate rich clinical evidence." He also expressed his ambition, saying, "In the future, we will pursue official inclusion in health insurance after passing a new medical technology evaluation, lead medical innovation with AI technology, and contribute to saving more lives." Founded by professors from the Department of Radiology at Seoul National University Bundang Hospital, medical AI startup Monitor Corporation has continued rapid growth by swiftly developing high-quality solutions needed in the field based on its specialized medical knowledge. Recognized for its outstanding technological capabilities and extensive industry experience, it has successfully attracted investment from leading domestic investors such as Naver D2SF, Bluepoint Partners, and Premier Partners, thereby solidifying its position as a frontrunner in the medical AI field.